Stapokibart

• CAT Number: I040378
• CAS Number: 2734715-10-5
• Purity: ≥95%

Stapokibart(CAT: I040378) is a humanized IgG4 monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4Rα), effectively blocking both IL-4 and IL-13 signaling pathways central to type 2 inflammatory responses. Developed for the treatment of moderate-to-severe atopic dermatitis, it has also shown efficacy in chronic rhinosinusitis with nasal polyps and seasonal allergic rhinitis. Stapokibart binds a distinct epitope on IL-4Rα, offering strong receptor blockade with a favorable safety profile. Its cross-species activity and rapid symptom relief make it a promising therapeutic and research tool. Supplied at high purity, Stapokibart supports advanced studies in immunology, dermatology, and respiratory allergy.

Reference

[1]. Yuan Zhang, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5:61:102076.
[Content Brief]